Preclinical testing of experimental therapeutics for treating bra | 47963

Journal of Neurology & Neurophysiology

ISSN - 2155-9562

Preclinical testing of experimental therapeutics for treating brain tumors: Raising the bar for clinical trial evaluation

International Conference and Exhibition on Neurology & Therapeutics

May 14-16, 2012 Embassy Suites Las Vegas, USA

David James

Key Note Forum: J Neurol Neurophysiol

Abstract :

This lecture will address a variety of topics related to the use of rodent models for pre-clinical evaluation of candidate therapeutics for treating brain tumors, and will include discussion of: maintenance options for tumor cell sources; the importance of appropriate anatomic modeling; brain tumor imaging approaches for orthotopic rodent models (bioluminescence and magnetic resonance); factors affecting experimental outcomes; use of therapeutic nanoparticles and associated administration options; acquired resistance to therapy; and novel combination therapies. In addition to these subjects, attendees of this lecture will be familiarized with the need for rigorous and stringent testing of candidate therapeutics, so that only the most promising therapies are advanced to clinical trial evaluation of efficacy when treating brain tumor patients.

Biography :

Professor James has studied brain tumor molecular biology and therapeutics for 25+ years, during which time he has authored more than 150 peer-reviewed reports. He has served on the editorial boards for the Clinical Cancer Research, Journal of Neuropathology & Experimental Neurology, and the International Journal of Oncology, and he is a Senior Editor for Neuro-Oncology. Dr. James is a member of the Scientific Advisory Committees for the Pediatric Brain Tumor Foundation and the National Brain Tumor Society, and h e has served on numerous review committees for the NIH, including his current membership with the CNBT study section.